Relmada Therapeutics, Inc. (RLMD) stock

RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30

$4.16−0.27 (-6.09%)

Close on Nov 12, 2026Market cap $443.75MP/E –Yield –

Relmada Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Relmada Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?